- Home
- NEGG vs ARVN Comparison
NEGG vs ARVN Comparison
Compare NEGG & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEGG | ARVN |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United States |
| Employees | 762 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.1M | 781.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | NEGG | ARVN |
|---|---|---|
| Price | $44.32 | $13.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 21 |
| Target Price | N/A | ★ $15.57 |
| AVG Volume (30 Days) | 43.3K | ★ 722.7K |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.21 | $5.90 |
| 52 Week High | $137.84 | $18.93 |
Technical Indicators
Market Signals| Indicator | NEGG | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 40.61 | 62.00 |
| Support Level | $42.81 | $11.07 |
| Resistance Level | $56.73 | $13.97 |
| Average True Range (ATR) | 3.35 | 0.82 |
| MACD | -0.62 | 0.13 |
| Stochastic Oscillator | 27.95 | 97.44 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.